Lung delivery of salbutamol given by breath activated pressurized aerosol and dry powder inhaler devices

被引:21
作者
Lipworth, BJ [1 ]
Clark, DJ [1 ]
机构
[1] Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol, Dundee DD1 9SY, Scotland
关键词
salbutamol; bioavailability; deposition; breath activated; dry powder inhaler; pressurized metered dose aerosol; chlorofluorocarbon;
D O I
10.1006/pupt.1997.0093
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Poor inhalation technique is prevalent in asthmatics using standard metered dose inhalers (MDI). Both dry powder inhalers (DPI) and breath activated MDIs offer a solution to this problem. Our aim was to compare the lung delivery of salbutamol from two DPIs, Diskhaler and Diskus (Accuhaler), and the Easi-Breathe breath activated MDI. Ten healthy volunteers mean (SEM) age 24.0 years (1.7) were studied in a randomized single (investigator) blind crossover design. Single 1200 pg nominal doses of salbutamol via Diskhaler and Diskus (6 sequential 200 mu g puffs) and Easi-Breathe (12 sequential 100 mu g puffs) were given over 6 min. Mouth rinsing was performed after every inhalation sequence. Lung delivery was evaluated by measuring the early lung absorption profile of salbutamol at 5, 10, 15 and 20 min after inhalation, with calculation of peak (C-max) and average over 20 min (C-av) concentration (ng/ml). Both the Diskhaler and the Easi-Breathe produced significantly greater salbutamol C-max and C-av than Diskus (as mean and 96% CI for difference vs. Diskus): [C-max] Diskus 3.22 vs. Diskhaler 4.35 (95% CT 0.19 to 2.08), vs. Easi-Breathe 3.98 (95% CI -0.18 to 1.71). [C-av] Diskus 2.62 vs. Diskhaler 3.95 (95% CI 0.52 to 2.14), vs. Easi-Breathe 3.52 (95% CI 0.09 to 1.71). For C-av this amounted to a 1.51-fold difference (95% CI 1.35 to 1.68) between Diskhaler vs. Diskus, and a 1.36-fold difference (95% CI 1.03 to 1.69) for Easi-Breathe vs. Diskus. In conclusion we found that, in vivo, the Diskus DPI produced significantly lower lung delivery for the same nominal dose of salbutamol than either Diskhaler DPI or the Easi-Breathe pressurised aerosol. This shows that breath activated inhaler devices may have different in vivo deposition characteristics for delivering the same drug. (C) 1997 Academic Press Limited.
引用
收藏
页码:211 / 214
页数:4
相关论文
共 15 条
[1]   Lung bioavailability of generic and innovator salbutamol MDIs [J].
Chrystyn, H ;
Corlett, SA ;
Silkstone, V .
THORAX, 1996, 51 (06) :658-658
[2]   Effect of multiple actuations, delayed inhalation and antistatic treatment on the lung bioavailability of salbutamol via a spacer device [J].
Clark, DJ ;
Lipworth, BJ .
THORAX, 1996, 51 (10) :981-984
[3]   Lung bioavailability of generic and innovator salbutamol metered dose inhalers [J].
Clark, DJ ;
GordonSmith, J ;
McPhate, G ;
Clark, G ;
Lipworth, BJ .
THORAX, 1996, 51 (03) :325-326
[4]   Lung bioavailability of chlorofluorocarbon free, dry powder and chlorofluorocarbon containing formulations of salbutamol [J].
Clark, DJ ;
Lipworth, BJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 41 (03) :247-249
[5]  
CROMPTON GK, 1982, EUR J RESPIR DIS, V63, P101
[6]   Pharmacokinetics of inhaled drugs [J].
Lipworth, BJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 42 (06) :697-705
[7]   BETA-ADRENOCEPTOR RESPONSES TO INHALED SALBUTAMOL IN NORMAL SUBJECTS [J].
LIPWORTH, BJ ;
MCDEVITT, DG .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 36 (03) :239-245
[8]  
LIPWORTH BJ, 1989, EUR J CLIN PHARMACOL, V37, P567
[9]  
Mackie A. E., 1997, British Journal of Clinical Pharmacology, V43, p540P
[10]   IMPROVEMENT OF DRUG DELIVERY WITH A BREATH ACTUATED PRESSURIZED AEROSOL FOR PATIENTS WITH POOR INHALER TECHNIQUE [J].
NEWMAN, SP ;
WEISZ, AWB ;
TALAEE, N ;
CLARKE, SW .
THORAX, 1991, 46 (10) :712-716